Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | phosphoglycerate mutase family protein, putative | 0.0034 | 0.2852 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0034 | 0.2852 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0057 | 1 | 1 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0056 | 0.9706 | 0.9706 |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0057 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0056 | 0.9706 | 0.9604 |
Echinococcus multilocularis | 6 phosphofructo 2 kinase:fructose 2 | 0.0057 | 1 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.0056 | 0.9706 | 0.9706 |
Loa Loa (eye worm) | hypothetical protein | 0.0057 | 1 | 1 |
Onchocerca volvulus | 0.0057 | 1 | 0.5 | |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0057 | 1 | 1 |
Trypanosoma brucei | 6-phosphofructo-2-kinase 2 | 0.0056 | 0.9706 | 0.9706 |
Mycobacterium ulcerans | fructose-2,6-bisphosphatase GpmB | 0.0034 | 0.2852 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.0034 | 0.2852 | 0.5 |
Schistosoma mansoni | 6-phosphofructokinase | 0.0057 | 1 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.0056 | 0.9706 | 0.9706 |
Giardia lamblia | Hypothetical protein | 0.0034 | 0.2852 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0057 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | 9 % | Ability of the compound to induce cells in G0/G1 phase | ChEMBL. | 15369401 |
Activity (functional) | 9 % | Ability of the compound to induce cells in G0/G1 phase | ChEMBL. | 15369401 |
Activity (functional) | 30 % | Ability of the compound to induce cells in S phase | ChEMBL. | 15369401 |
Activity (functional) | 30 % | Ability of the compound to induce cells in S phase | ChEMBL. | 15369401 |
Activity (functional) | 60 % | Ability of the compound to induce cells in G2/M phase | ChEMBL. | 15369401 |
Activity (functional) | 60 % | Ability of the compound to induce cells in G2/M phase | ChEMBL. | 15369401 |
GI50 (functional) | = 14.5 uM | Growth inhibitory concentration is the concentration that reduced K562 cell growth by 50% | ChEMBL. | 15369401 |
GI50 (functional) | = 14.5 uM | Growth inhibitory concentration is the concentration that reduced K562 cell growth by 50% | ChEMBL. | 15369401 |
IC50 (functional) | = 0.8 uM | Inhibitory concentration of the compound against K562 cell line | ChEMBL. | 15369401 |
IC50 (functional) | = 0.8 uM | Inhibitory concentration of the compound against K562 cell line | ChEMBL. | 15369401 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | 15369401 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.